Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 464-466

  Gerin, Magdalena ^a,b,c   Mahlaoui, Nizar ^a,c,d,j   Elie, Caroline ^a,e   Lanternier, Fanny ^a,b,c   Bougnoux, Marie Elisabeth ^a,c,f   Blanche, Stéphane ^a,c,d   Lortholary, Olivier ^a,b,c,g,h   Jullien, Vincent ^a,i  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Centre d'Infectiologie Necker Pasteur   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d Unité D'Immunologie Hématologie Pédiatriques   (France)

^e Service de Biostatistique   (France)

^f Service de Microbiologie   (France)

^g INSTITUT PASTEUR   (France)

^h CNRS   (France)

ⁱ HÔPITAL SAINT VINCENT DE PAUL   (France)

^j Centre de Référence Déficits Immunitaires Héréditaires   (France)

more..

Author keywords

Children; Immunodeficiency; Infants; Intravenous administration; Primary immunodeficiency; Therapeutic drug monitoring; Voriconazole

Indexed keywords

VORICONAZOLE;

ADOLESCENT; ARTICLE; CHILD; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE DEFICIENCY; INFANT; LIVER TOXICITY; MALE; MYCOSIS; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INJECTIONS, INTRAVENOUS; MALE; MYCOSES; PYRIMIDINES; TREATMENT FAILURE; TRIAZOLES;

EID: 80051790316     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182241b2b     Document Type: Article

References (10)

1. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935-944.
2. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54: 1050-1052.
3. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211. (Pubitemid 351269158)
4. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235-243. (Pubitemid 43146453)
5. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570-1572.
6. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
7. Chhun S, Rey E, Tran A, et al. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:223-228. (Pubitemid 46839210)
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46: 1813-1821.
9. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1): 56-61. (Pubitemid 37491735)
10. Bruggemann RJ, van der Linden JW, Verweij PE, et al. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30:533-534.